SAN DIEGO, April 28 2020 /PRNewswire/ –?Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today?announced that the company will participate in two upcoming investor conferences.?
Details of the company’s participation are as follows:
- 2020 6th Annual SunTrust Robinson Humphrey (STRH) Life Sciences Summit
Details: Viking management will participate in a fireside chat and 1-on-1 meetings
Conference Date: May 5-6, 2020
Fireside Chat Time/Date: 3:00 p.m. Eastern on Wednesday, May 6, 2020
Format: Virtual Conference
- UBS Virtual Global Healthcare Conference 2020
Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings
Conference Date: May 18-20, 2020
Presentation Time/Date: 3:00 p.m. Eastern on Monday, May 18, 2020
Format: Virtual Conference
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.? Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives.? The company’s clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, including NASH.? In a Phase 2 trial for the treatment of NAFLD and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.? The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD).
Viking’s other programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator.? In a Phase 2 trial in patients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared with patients who received placebo.? Other programs also include two earlier-stage programs targeting metabolic diseases and anemia.? The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
Follow Viking on Twitter @Viking_VKTX.
View original content to download multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301047863.html
SOURCE Viking Therapeutics, Inc.